Global Human Microbiome Market – Overview
The global market for human microbiome is projected to showcase a considerable potential in the coming years of the forecast period. The growth of the global market is expected to be driven primarily because of the vast levels of untapped medical requirements across the world. Currently, the human microbiome market is at its stage of inception. Even the therapies and techniques are in the clinical and pre-clinical stages. Diagnostics are also currently under the stage of development phase. In November 2016, a company named uBiome announced the launch of the SmartGut test. This test helps in diagnosis of gut health diseases. Companies operating in the global human microbiome market have now started to allot considerable amount of investments and funding for the activities of research and development. They are also investing heavily for the management of clinical researches and studies for new and innovative diagnostics and therapies.
In the current market scenario, there is a serious lack of targeted drugs for certain conditions such as ulcerative colitis and C.difficile infection among others. This has presented a highly lucrative growth opportunity for the companies operating in the global human microbiome market. They are now planning to introduce their new and innovative drugs in the market that have the potential of being a huge commercial success. The human microbiome consists of genetic material inside a microbiota. A microbiota is an entire collection of wide range of microorganisms such as archea, fungi, virus, bacteria, and others in certain areas of human body such as the oral cavity, vagina, gut, and elsewhere.
Request For Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999
Rising Clinical Trials to Aid in Market Development
The global human microbiome market is being influenced by myriad of factors. In recent years, there has been a tremendous growth in terms of clinical trials for disorders related to gut health. Moreover, there has been a substantial increase in terms of funding and investment provided by venture capitalists, group of investors, and individual investors for the promotion of research and development activities related to human microbiome therapies.
Lack of Uncertainty Related to Drug Performance May Hamper Market Growth
There are however, some factors that might impede the growth of the global human microbiome market and may stop it from reaching its full potential. Currently, a serious lack of uncertainty about the overall performance of these human microbiome based drugs in the long run is expected to slow down the growth of the global market. In addition to this, there are several regulatory issues and challenges that are slowing down the time to market, affecting the overall growth. Nonetheless, the global market for human microbiome is projected to witness wide ranging development opportunities. With the growing preference of patients for rapid, descriptive, and minimally invasive sequence based microbiome diagnostic tests for different diseases such as Crohn’s disease, vaginosis, colon cancer among others, the global market is expected to tackle the aforementioned challenges in the due course of time.
Given the potential of the growth of the global human microbiome diagnostics is projected to showcase a highly promising CAGR of 9.8% over the course of the given forecast period ranging from 2018 to 2026. On the other hand, the global human microbiome therapeutics market is expected to show a similar robust CAGR of 9.6% over the forecast period ranging from 2024 to 2026. The global market for human microbiome diagnostics is being driven by the increasing demand for untapped and unmet clinical needs for effective disease management. Moreover, growing expenditure on the activities of research and development is also expected to drive the overall growth of the global market.
The valuation of the global human microbiome diagnostics market stood at US$892.1 Mn in the year 2018. Given the rate of growth, the valuation of the market by the end of the forecast period in 2026 is projected to be around US$1,888.9 Mn. On the other hand, the human microbiome therapeutics market is projected to reach a valuation of US$1,245.3 Mn in 2024. And given the rate of growth, the valuation of the market is expected to reach around the mark of US$2,160.9 Mn by the fall of 2026.
In terms of therapeutic application/area, the global market for human microbiome therapeutics is segmented into skin disorders, women’s health, metabolic disorders, gastrointestinal disorders, and others. The other key segments of the therapeutic areas include rare diseases, autoimmune diseases, infections, and infant health. Of these, the segment of gastrointestinal disorders is projected to dominate the global market in the coming years of the forecast period. The growth of the segment is primarily driven due to the availability of large number of therapies that have been under clinical trials. Moreover, increasing cry to fulfill the unmet demands of gut health related concerns is also projected to drive the growth of the segment in the near future.
Request For Covid19 Impact Analysis Across Industries And Markets @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=3999
The global market for human microbiome diagnostics can be segmented in terms of technology, indication, and region. The segments of metabolic and gastrointestinal disorders are expected to showcase highly promising growth opportunities in the coming years of the forecast period. The overall incremental growth of these two segments is expected to be around US$586.9 Mn for a period ranging from 2018 to 2026.
In terms of regional segmentation, the global market for human microbiome is segmented into five key regions viz. North America, Latin America, Middle East and Africa, Europe, and Asia Pacific. Of these, the segment of North America is expected to lead the global market in the coming years of the forecast period.
Some of the key companies operating in the global market are AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences, Enterome, Biosciences, and Synthetic Biologics, Inc. Related Reports Press-Release
- https://www.prnewswire.com/news-releases/increase-in-incidence-of-nosocomial-infections-to-underscore-growth-in-hospital-acquired-disease-testing-market-from-2019-to-2027-tmr-301061519.html
- https://www.prnewswire.com/news-releases/outbreak-of-covid-19-to-boost-the-growth-of-global-sterilization-services-market-during-the-tenure-of-2019-to-2027-tmr-301062487.html
- https://www.prnewswire.co.uk/news-releases/global-pharmaceutical-excipients-market-to-expand-as-fda-ramps-up-approval-of-new-drug-classes-tmr-817327344.html
